A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determination of dose limiting toxicity (DLT) and maximum tolerated dose (MTD)
14 days on therapy and 7 days off therapy OR 21 days continuous dosing
Yes
Sari Enschede, MD
Study Director
AbbVie
United States: Food and Drug Administration
M06-873
NCT00481091
July 2007
September 2014
Name | Location |
---|---|
Site Reference ID/Investigator# 5566 | La Jolla, California 92093-0820 |
Site Reference ID/Investigator# 5547 | Boston, Massachusetts 02115 |
Site Reference ID/Investigator# 12261 | Omaha, Nebraska 68198-7680 |
Site Reference ID/Investigator# 12267 | New Hyde Park, New York 11040 |
Site Reference ID/Investigator# 5575 | Houston, Texas 77030-4009 |
Site Reference ID/Investigator# 26428 | Tacoma, Washington 98405 |